Projects per year
The nuclease-deactivated variant of CRISPR-Cas9 proteins (dCas9) fused to heterologous transactivation domains can act as a potent guide RNA sequence-directed inducer or repressor of gene expression in mammalian cells. In such a system the long-term presence of a stable dCas9 effector can be a draw-back precluding the ability to switch rapidly between repressed and activated target gene expression states, imposing a static environment on the synthetic regulatory circuits in the cell. To address this issue we have generated a toolkit of conditionally degradable or stabilisable orthologous dCas9 or Cpf1 effector proteins, thus opening options for multidimensional control of functional activities through combinations of orthogonal, drug-tunable artificial transcription factors.
|Publication status||Published - 30 Oct 2017|
- Journal Article
FingerprintDive into the research topics of 'Drug-tunable multidimensional synthetic gene control using inducible degron-tagged dCas9 effectors'. Together they form a unique fingerprint.
- 2 Finished
A Combinatorial Approach to Enhance Production of Monoclonal Antibodies
1/06/16 → 31/05/21
SynthSys-Mammalian: Edinburgh Mammalian Synthetic Biology Research Centre
14/11/14 → 31/03/22
- School of Biological Sciences - Chair of Synthetic Biology
- Centre for Engineering Biology
Person: Academic: Research Active